Myeloid-Derived Suppressor Cells: Critical Cells Driving Immune Suppression in the Tumor Microenvironment

• Published in: Advances in cancer research Vol. 128; pp. 95 - 139
• Main Authors: Parker, Katherine H, Beury, Daniel W, Ostrand-Rosenberg, Suzanne
• Format: Journal Article
• Language: English
• Published: United States 2015
• Subjects: Animals; Humans; Immunosuppression; Inflammation - immunology; Myeloid Cells - immunology; Neoplasms - immunology; Neoplasms - pathology; Neoplasms - therapy; Tumor Microenvironment - immunology; Cytokines; Tumor-infiltrating lymphocytes; Immature myeloid cells; Immunotherapy; STAT3; cEBPbeta; Tumor-induced immune suppression; Inflammation; Myeloid cell cross talk; Macrophages
• ISSN: 2162-5557; 0065-230X; 2162-5557
• DOI: 10.1016/bs.acr.2015.04.002

Myeloid-derived suppressor cells (MDSCs) are a heterogeneous population of immature myeloid cells that suppress innate and adaptive immunity. MDSCs are present in many disease settings; however, in cancer, they are a major obstacle for both natural antitumor immunity and immunotherapy. Tumor and host cells in the tumor microenvironment (TME) produce a myriad of pro-inflammatory mediators that activate MDSCs and drive their accumulation and suppressive activity. MDSCs utilize a variety of mechanisms to suppress T cell activation, induce other immune-suppressive cell populations, regulate inflammation in the TME, and promote the switching of the immune system to one that tolerates and enhances tumor growth. Because MDSCs are present in most cancer patients and are potent immune-suppressive cells, MDSCs have been the focus of intense research in recent years. This review describes the history and identification of MDSCs, the role of inflammation and intracellular signaling events governing MDSC accumulation and suppressive activity, immune-suppressive mechanisms utilized by MDSCs, and recent therapeutics that target MDSCs to enhance antitumor immunity.